Chai Jessie L, Siegmund Stephanie E, Hirsch Michelle S, Silverman Stuart G
Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, 75 Francis St, Boston, MA, 02115, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Abdom Radiol (NY). 2024 Jun;49(6):1940-1948. doi: 10.1007/s00261-023-04167-7. Epub 2024 Feb 19.
The 2022 World Health Organization classification of renal neoplasia expanded the spectrum of oncocytic neoplasms to encompass newly established and emerging entities; one of the latter is the low-grade oncocytic tumor (LOT). This study reports the radiologic appearance and clinical behavior of LOT.
In this IRB-approved, HIPPA-compliant retrospective study, our institution's pathology database was searched for low-grade oncocytic tumors or neoplasms. Patient age, gender, and comorbidities were obtained from a review of electronic medical records, and imaging characteristics of the tumors were assessed through an imaging platform.
The pathology database search yielded 14 tumors in 14 patients. Four patients were excluded, as radiologic images were not available in three, and one did not fulfill diagnostic criteria after pathology re-review. The resulting cohort consisted of 10 tumors (median diameter 2.3 cm, range 0.7-5.1) in 10 patients (median age 68 years, range 53-91, six women). All tumors presented as a solitary, well-circumscribed, mass with solid components. All enhanced as much or almost as much as adjacent renal parenchyma; all but one enhanced heterogeneously. None had lymphadenopathy, venous invasion, or metastatic disease at presentation or at clinical follow-up (median, 22.2 months, range 3.4-71.6). Among five tumors undergoing active surveillance, mean increase in size was 0.4 cm/year at imaging follow-up (median 16.7 months, range 8.9-25.4).
LOT, a recently described pathologic entity in the kidney, can be considered in the differential diagnosis of an avidly and typically heterogeneously enhancing solid renal mass in an adult patient.
2022年世界卫生组织肾肿瘤分类扩大了嗜酸性细胞瘤的范畴,纳入了新确立和新出现的实体;后者之一是低级别嗜酸性细胞瘤(LOT)。本研究报告了LOT的放射学表现及临床行为。
在这项经机构审查委员会批准且符合健康保险流通与责任法案的回顾性研究中,我们在本机构的病理数据库中搜索低级别嗜酸性细胞瘤或肿瘤。通过查阅电子病历获取患者的年龄、性别及合并症,并通过影像平台评估肿瘤的影像特征。
病理数据库检索发现14例患者中有14个肿瘤。4例患者被排除,其中3例没有放射影像,1例经病理复查后不符合诊断标准。最终队列包括10例患者的10个肿瘤(中位直径2.3 cm,范围0.7 - 5.1 cm)(中位年龄68岁,范围53 - 91岁,6名女性)。所有肿瘤均表现为孤立的、边界清晰的实性肿块。所有肿瘤增强程度与相邻肾实质相同或几乎相同;除1个肿瘤外均呈不均匀强化。在初诊或临床随访时(中位时间22.2个月,范围3.4 - 71.6个月),均未发现淋巴结肿大、静脉侵犯或转移疾病。在5个接受主动监测的肿瘤中,影像随访时大小的平均年增长为0.4 cm(中位时间16.7个月,范围8.9 - 25.4个月)。
LOT是一种最近描述的肾脏病理实体,在鉴别诊断成年患者中强化明显且通常不均匀强化的实性肾肿块时可予以考虑。